Indian Pediatrics

, Volume 55, Issue 12, pp 1050–1055 | Cite as

Safety and Immunogenicity of Two Doses of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Indian and Russian Children Aged 9 to 17 Months

  • Bakul Javadekar
  • Apurba Ghosh
  • Rajeev Zachariah Kompithra
  • Shally Awasthi
  • Olga Perminova
  • Viktor Romanenko
  • Vera Rodnikova
  • Susanna Kharit
  • Yael Thollot
  • Valerie Bosch-Castells
  • Alexander Goldstein
  • Himanshu Dubey
Research Paper



Evaluation of tolerability, safety and immunogenicity of a two-dose series of a quadrivalent meningococcal polysaccharide diptheria toxoid conjugate (ACYW-D) vaccine in Indian and Russian infants/toddlers.


Open-label, single-arm, phase III multi-national trial.

Study participants

300 children aged 9–17 months, previously unvaccinated against meningococcal disease from four sites each in India (n=200) and the Russian Federation (n=100).


Two 0.5 mL doses of ACYW-D by intramuscular injection, 3–6 months apart.

Main outcome measures

Meningococcal antibody titers to serogroups A, C, W-135 and Y, determined using a serum bactericidal assay in the presence of human complement before vaccination and 28 days after the second vaccination. Titers ≥1:8 against either/all of the A, C, W-135 or Y were considered seroprotective.


After dose 2, 95.7–99.5% and 92.9–99.0% of infants/ toddlers achieved seroprotection across the four serogroups in India and the Russian Federation, respectively. No immediate adverse events were reported after any dose of ACYW-D. Solicited reactions were reported in 49.2% of participants, and were mainly of Grade 1 severity, and resolved within three days. Unsolicited adverse events were reported in 19.1% of infants: one event (Grade 3 diarrhea, resolving within one day) was considered related to study vaccine. No non-serious adverse events led to premature withdrawal from the study. Four serious adverse events were reported; none were considered related to study vaccine. No deaths occurred during the study.


A two-dose series of ACYW-D vaccine in Indian and Russian children (9-17 month) was well-tolerated with no safety concerns, and induced robust bactericidal antibody responses against the meningococcal serogroups contained in the vaccine.


Bactericidal assay Immunization Meningococcus Prevention 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Manchanda V, Gupta S, Bhalla P. Meningococcal disease: History, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. Indian J Med Microbiol. 2006;24:7–19.CrossRefGoogle Scholar
  2. 2.
    Pace D, Pollard AJ. Meningococcal disease: Clinical presentation and sequelae. Vaccine. 2012;30:062.CrossRefGoogle Scholar
  3. 3.
    Titova L, Samodova O, Buzinov R, Gordienko T. Epidemiology of meningococcal infection in arkhangelskoblast. Available from: http://wwwepinorthorg/eway/defaultaspx?pid=230&trg=Area_5268&MainArea_5 260=5263:0:15,2946:1:0:0:::0:0&Area_5263=5268:44984::1: 5264: 1:::0:0&Area_5268=5273:47185::1:5266:3:::0:0. Accessed June 19, 2017.Google Scholar
  4. 4.
    Koroleva IS, Maxina TA, Zakroeva M, Beloshitsky GV, Lytkina IN, Pyaeva AP. Epidemiology of invasive meningococcal disease in Moscow, 2005–2010. Available from: Accessed June 19, 2017.Google Scholar
  5. 5.
    Sinclair D, Preziosi MP, Jacob John T, Greenwood B. The epidemiology of meningococcal disease in India. Trop Med Int Health. 2010;15:1421–35.CrossRefGoogle Scholar
  6. 6.
    John TJ, Gupta S, Chitkara AJ, Dutta AK, Borrow R. An overview of meningococcal disease in India: knowledge gaps and potential solutions. Vaccine. 2013;31:2731–7.CrossRefGoogle Scholar
  7. 7.
    Borrow R, Lee JS, Vazquez JA, Enwere G, Taha MK, Kamiya H, et al. Meningococcal disease in the Asia–Pacific region: Findings and recommendations from the Global Meningococcal Initiative. Vaccine. 2016;34: 5855–62.CrossRefGoogle Scholar
  8. 8.
    Jafri RZ, Ali A, Messonnier NE, Tevi–Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11:17.CrossRefGoogle Scholar
  9. 9.
    Borrow R, Alarcon P, Carlos J, Caugant DA, Christensen H, Debbag R, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28.CrossRefGoogle Scholar
  10. 10.
    Koroleva I, Beloshitskij G, Zakroeva I, Melnikova A, Koroleva M, Shipulin G, et al. Invasive meningococcal disease in Russian Federation. In: European Meningococcal Disease Society. 20 years EMGM. Bad Loipersdorf, Austria. 17–19 September 2013. p71. Available from: Accessed April 13, 2017.Google Scholar
  11. 11.
    Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine. 2016;34:5273–8.CrossRefGoogle Scholar
  12. 12.
    Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J. 2012; 31:1173–83.CrossRefGoogle Scholar
  13. 13.
    Pelton SI, Gilmet GP. Expanding prevention of invasive meningococcal disease. Expert Rev Vaccines. 2009;8: 717–27.Google Scholar
  14. 14.
    Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23:2222–7.CrossRefGoogle Scholar
  15. 15.
    Choudhuri D, Huda T, Theodoratou E, Nair H, Zgaga L, Falconer R, et al. An evaluation of emerging vaccines for childhood meningococcal disease. BMC Public Health. 2011;11:S29.Google Scholar
  16. 16.
    Halperin SA, Diaz–Mitoma F, Dull P, Anemona A, Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. European J Clin Microb Infect Dis. 2010;29:259–67.CrossRefGoogle Scholar
  17. 17.
    Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8:616–23.Google Scholar
  18. 18.
    Hansen J, Zhang L, Eaton A, Baxter R, Robertson CA, Decker MD, et al. Post–licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY–D) in infants and children. Vaccine. 2018;36:2133–8.CrossRefGoogle Scholar
  19. 19.
    Noya F, McCormack D, Reynolds DL, Neame D, Oster P. Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12–to 18–month–old children. Can J Infect Dis Med Microbiol. 2014;25:211–6.CrossRefGoogle Scholar
  20. 20.
    Yadav S, Manglani MV, Narayan DA, Sharma S, Ravish HS, Arora R, et al. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW–DT): a multicenter, open–label, nonrandomized, phase III clinical trial. Indian Pediatr. 2014; 51:451–6.CrossRefGoogle Scholar

Copyright information

© Indian Academy of Pediatrics 2018

Authors and Affiliations

  • Bakul Javadekar
    • 1
  • Apurba Ghosh
    • 2
  • Rajeev Zachariah Kompithra
    • 3
  • Shally Awasthi
    • 4
  • Olga Perminova
    • 5
  • Viktor Romanenko
    • 6
  • Vera Rodnikova
    • 7
  • Susanna Kharit
    • 8
  • Yael Thollot
    • 9
  • Valerie Bosch-Castells
    • 10
  • Alexander Goldstein
    • 11
  • Himanshu Dubey
    • 12
    • 13
  1. 1.Department of Pediatrics, Medical College and SSG Hospital, BarodaSSG Hospital Campus, Raopura, VadodaraGujaratIndia
  2. 2.Institute of Child HealthKolkataIndia
  3. 3.Well Baby Clinic, Department of Child HealthChristian Medical CollegeVelloreIndia
  4. 4.Department of PediatricsShahuji Maharaj Medical UniversityLucknowIndia
  5. 5.City Children’s Policlinic No 5PermRussia
  6. 6.Municipal City Children Hospital # 11EkaterinburgRussia
  7. 7.Murmansk Children’s City HospitalMurmanskRussia
  8. 8.Research Institute for Pediatric Infectious DiseasesSt. PetersburgRussia
  9. 9.Sanofi PasteurLyonFrance
  10. 10.Sanofi PasteurMarcy l’EtoileFrance
  11. 11.Sanofi PasteurMoscowRussia
  12. 12.Medical AffairsSanofi PasteurMumbaiIndia
  13. 13.House, CTS No. 117-B, L&T Business ParkSaki Vihar RoadPowaiIndia

Personalised recommendations